| Fonds | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | |
| 839.229.482 $ | -203.427.936 $ | -7,6 % | 1.123.786.471 $ | +464.923.296 $ | +115,5 % | 485.016.449 $ | +255.508.074 $ | +111,3 % | |
| Frazier Life Sciences Management, L.P. | 136.333.129 $ | -52.889.033 $ | -28,0 % | 189.222.162 $ | +70.792.747 $ | +59,8 % | 118.429.415 $ | +62.388.951 $ | +111,3 % |
| TRV GP IV, LLC | 133.547.646 $ | -51.808.434 $ | -28,0 % | 185.356.080 $ | +27.858.349 $ | +17,7 % | 157.497.731 $ | +82.970.266 $ | +111,3 % |
| Deep Track Capital, LP | 103.805.226 $ | -72.124.783 $ | -41,0 % | 175.930.009 $ | +73.534.773 $ | +71,8 % | 102.395.236 $ | +53.942.110 $ | +111,3 % |
| Janus Henderson Group Ltd. | 85.280.271 $ | -44.917.108 $ | -34,5 % | 130.197.379 $ | +110.708.805 $ | +568,1 % | |||
| ARCH Venture Management, LLC | 122.983.582 $ | +72.389.331 $ | +143,1 % | ||||||
| BlackRock, Inc. | 76.727.187 $ | -18.029.644 $ | -19,0 % | 94.756.831 $ | +60.632.536 $ | +177,7 % | |||
| Paradigm Biocapital Advisors LP | 81.920.310 $ | ||||||||
| a16z Capital Management, L.L.C. | 50.811.416 $ | -19.711.766 $ | -28,0 % | 70.523.182 $ | +26.384.488 $ | +59,8 % | 44.138.694 $ | +23.252.393 $ | +111,3 % |
| VANGUARD GROUP INC | 70.307.332 $ | +35.691.949 $ | +103,1 % | ||||||
| Venrock Adviser, LLC | 47.820.715 $ | -16.336.499 $ | -25,5 % | 64.157.214 $ | +32.243.374 $ | +101,0 % | |||
| Alphabet Inc. | 57.528.994 $ | -5.026.379 $ | -8,0 % | 62.555.373 $ | +32.954.354 $ | +111,3 % | |||
| General Catalyst Group Management, LLC | 42.917.751 $ | +16.056.605 $ | +59,8 % | ||||||
| Woodline Partners LP | 42.889.537 $ | +16.046.049 $ | +59,8 % | ||||||
| 839.229.482 $ | -203.427.936 $ | -7,6 % | 1.123.786.471 $ | +464.923.296 $ | +115,5 % | 485.016.449 $ | +255.508.074 $ | +111,3 % | |